EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • April 1st, 2024 • Aspira Women's Health Inc. • In vitro & in vivo diagnostic substances
This Exclusive License Agreement, effective as of March 1st 2023 (“Effective Date”), is between the Dana-Farber Cancer Institute, Inc., a Massachusetts non-profit organization having a principal place of business at 450 Brookline Ave., Boston, MA 02215 (“DFCI”) and Aspira Women’s Health Inc., a corporation having a principal place of business at 35 Nutmeg Drive, Suite 260, Trumbull, CT06611 (“LICENSEE”). Each of DFCI and LICENSEE may be referred to herein as a “Party” or collectively as the “Parties.”
AMENDMENT NO. 5 TO TESTING AND SERVICES AGREEMENTTesting and Services Agreement • April 1st, 2024 • Aspira Women's Health Inc. • In vitro & in vivo diagnostic substances
NOW THEREFORE, in consideration of the mutual agreements contained herein, the parties agree the TSA is hereby amended as follows:
